Antidepressants help a great many people — and for others, relief proves partial or short-lived. Here is what the largest real-world depression study actually found, and what the emerging psychedelic research is showing, side by side and in context.
Depression is one of the most-treated conditions in America, and antidepressants are the front line. In 2023,11.4% of U.S. adults —roughly 1in 8 — reported taking prescription medication for depression(CDC/NCHS, National Health Interview Survey 2023). For millions, these medications are genuinely helpful. But a large group does everything right and stilldoesn’tget all the way better.
- 11.4%— of U.S. adults took prescription medication for depression · CDC/NCHS · NHIS 2023
- ~50%— did not remit after a first antidepressant in the largest real-world trial · STAR*D · Rush et al., 2006
- 3%— had a sustained remission a year later (108 of 4,041 enrolled) · STAR*D · reanalysis, Pigott 2023
What STAR*D Actually found
STAR*D (Sequenced Treatment Alternatives to Relieve Depression) is the largest and longest real-world antidepressant study ever run — 4,041 outpatients, NIMH-funded, up to four medication steps. Headline cumulative remission ~67% (retrospective criteria); the 2023 Pigott reanalysis following original protocol put it near ~35%. Sustained remission at one year: only 108 of 4,041 (~3%).
“The antidepressant funnel, in one trial”:
- Remission after first antidepressant (Step 1): ~37%
- Cumulative remission, original protocol (reanalysis): ~35%
- Cumulative remission, as originally reported (all 4 steps): ~67%
- Sustained remission at ~1 year (108 of 4,041): ~3% Source: Rush et al., Am J Psychiatry 2006 (n=4,041); Pigott et al., BMJ Open 2023.
What the emerging psychedelic research shows
“What the trials have shown” (the graph already on the site):
- MDMA-assisted therapy — no longer met PTSD criteria · Phase 3, 2021: 67% (Mitchell et al., Nature Medicine 2021, n=90; vs 32%placebo+therapy)
- Psilocybin-assisted therapy — depression remission at follow-up · Johns Hopkins, 2021: 54% (Davis et al., JAMA Psychiatry 2021, n=27)
- Psilocybin — smoking abstinence at 6 months · Johns Hopkins, 2014: 80% (Johnson/Garcia-Romeu 2014, n=15)
- Standard SSRI care — sustained remission after 1 year · STAR*D: ~3%
Caveat box (required, keep verbatim tone): Early-stage, several small (n=27, n=15); different conditions/measures — context, not scoreboard. Pattern = meaningful effects where conventional options had already fallen short → why Phase 3 trials + FDA Breakthrough designations exist.
Why the mechanism may matter
Daily indefinite symptom management vs. a small number of supervised sessions + therapy aimed at lasting change. Neuroplasticity as a candidate mechanism (still being worked out —don’toverstate).
Where this leaves you
Common experience, not a personal failing. Alternatives promising but emerging, real medical/legal considerations. Ibogaine + 5-MeO-DMTrequiremedical screening incl. cardiac, in a supervised setting only.
Not sure where to start? Speak with an advisor who understands both the research and the landscape of ibogaine treatment. Independent, confidential, no pressure. → Speak With An Advisor / (866) 435-7057
Sources
- Rush AJ, et al. Am J Psychiatry, 2006 (n=4,041)
- Pigott HE, et al. BMJ Open, 2023 (reanalysis)
- CDC/NCHS Data Brief No. 528, April 2025 (11.4%)
- Mitchell JM, et al. Nature Medicine, 2021 (n=90)
- Davis AK, et al. JAMA Psychiatry, 2021 (n=27)
- Johnson MW, Garcia-Romeu A, et al. JPsychopharmacol, 2014 (n=15)
Jump to a Section
Call (855) 425-4846
